PsiOxus raised €34.7 Million from First-Class investors

19/05/2015 - 2 minutes

PsiOxus Therapeutics has closed a Series C financing round of €34.7M (£25 million) to progress its lead clinical candidate, enadenotucirev, and a pipeline of follow-on oncolytic programmes. Neil Woodford’s fund, GlaxoSmithKline’s VC unit and Imperial Innovations from Imperial College of London, amongst others, are behind the financing.

PsiOxus’ lead product, enadenotucirev, is an oncolytic virus that, in Phase I, has shown a selective infection in cancer cells when administered by intravenous infusion. The ability to deliver enadenotucirev systemically via intravenous infusion represents a significant advantage over the other oncolytic therapies currently in development that require intratumoural delivery. Furthermore, these enadenotucirev Phase I clinical trials have shown that the selective infection of tumour cells by the drug leads to the infiltration of immune cells (T-cells) into colorectal tumours.

PsiOxus will now use the new funding to conduct a Phase I clinical study combining enadenotucirev and an immune-checkpoint inhibitor in patients with metastatic colorectal cancer. With this study, PsiOxus aims to demonstrate that the immune process triggered by enadenotucirev infection of tumour cells,

This content is available exclusively to our paying members.

Our members receive the following benefits:

  • Unlock premium articles
  • Download our industry reports
  • Remove all banner ads
  • Access 1,500+ archived posts
  • Support our independent media
Already a member? Sign in
Do you want to remove this advert? Become a member!
Do you want to remove this advert? Become a member!

Support Us

Become a Member